The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
